Literature DB >> 9121699

High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease.

H Kunugi1, S Nanko, A Ueki, E Otsuka, M Hattori, F Hoda, H P Vallada, M J Arranz, D A Collier.   

Abstract

Catechol-O-methyltransferase (COMT) is an enzyme that inactivates catecholamines such as adrenaline, noradrenaline, dopamine, and levodopa. Recently an amino acid change (Val-108-Met) of the COMT protein was found to determine high and low activity alleles of the COMT gene. We genotyped 109 Japanese patients with Parkinson's disease (PD) and 153 controls by using polymerase chain reaction (PCR) amplification and digestion by the restriction enzyme NlaIII. The frequency of low activity allele in the controls was 0.29, which was significantly different from that reported in Caucasians (0.50). When comparison was made between patients with PD and controls, homozygosity for the low activity allele was significantly more common among the patients than among the controls (P = 0.017; odds ratio, 2.8, 95% CI 1.2-6.5), suggesting that homozygosity for the low activity allele may increase susceptibility to PD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9121699     DOI: 10.1016/s0304-3940(96)13289-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  20 in total

1.  Sexual dimorphism in xenobiotic genetic variants-mediated risk for Parkinson's disease.

Authors:  Nadella Kumudini; Addepally Uma; Shaik Mohammad Naushad; Rukmini Mridula; Rupam Borgohain; Vijay Kumar Kutala
Journal:  Neurol Sci       Date:  2014-01-04       Impact factor: 3.307

2.  Dopaminergic modulation of memory and affective processing in Parkinson depression.

Authors:  Lee X Blonder; John T Slevin; Richard J Kryscio; Catherine A Martin; Anders H Andersen; Charles D Smith; Frederick A Schmitt
Journal:  Psychiatry Res       Date:  2013-07-06       Impact factor: 3.222

Review 3.  Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

Authors:  John P M Finberg
Journal:  J Neural Transm (Vienna)       Date:  2018-11-01       Impact factor: 3.575

4.  Val158Met polymorphism of COMT gene and Parkinson's disease risk in Asians.

Authors:  Lixue Chuan; Jie Gao; Yuying Lei; Raoxiang Wang; Lechun Lu; Xianyu Zhang
Journal:  Neurol Sci       Date:  2014-07-25       Impact factor: 3.307

5.  Genetic Polymorphisms of Pharmacogenes among the Genetically Isolated Circassian Subpopulation from Jordan.

Authors:  Laith N Al-Eitan; Doaa M Rababa'h; Nancy M Hakooz; Mansour A Alghamdi; Rana B Dajani
Journal:  J Pers Med       Date:  2020-01-06

6.  Genetic contribution of catechol-O-methyltransferase in hippocampal structural and functional changes of female migraine sufferers.

Authors:  Jixin Liu; Lei Lan; Junya Mu; Ling Zhao; Kai Yuan; Yi Zhang; Liyu Huang; Fanrong Liang; Jie Tian
Journal:  Hum Brain Mapp       Date:  2015-01-19       Impact factor: 5.038

7.  Catechol-O-methyltransferase: effects of the val108met polymorphism on protein turnover in human cells.

Authors:  Anne E Doyle; James D Yager
Journal:  Biochim Biophys Acta       Date:  2007-10-16

8.  Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel.

Authors:  R Djaldetti; S Hassin-Baer; M J Farrer; C Vilariño-Güell; O A Ross; V Kolianov; S Yust-Katz; T A Treves; Y Barhum; M Hulihan; E Melamed
Journal:  J Neural Transm (Vienna)       Date:  2008-07-30       Impact factor: 3.575

9.  Association Between Catechol-O-Methyltransferase (COMT) Gene Polymorphisms, Parkinson's Disease, and Levodopa Efficacy.

Authors:  Bowen Yin; Yongqian Chen; Limei Zhang
Journal:  Mol Diagn Ther       Date:  2013-11-15       Impact factor: 4.074

10.  Low enzymatic activity haplotypes of the human catechol-O-methyltransferase gene: enrichment for marker SNPs.

Authors:  Andrea G Nackley; Svetlana A Shabalina; Jason E Lambert; Mathew S Conrad; Dustin G Gibson; Alexey N Spiridonov; Sarah K Satterfield; Luda Diatchenko
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.